[1] |
Centers for Disease Control and Prevention(CDC). Antibiotic resistance threats in the United States,2019[EB/OL].(2019-11-19)[2020-01-01]. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.
|
[2] |
MEYER E, SCHWAB F, JONAS D, et al. Surveillance of antimicrobial use and antimicrobial resistance in intensive care units(SARI):1. Antimicrobial use in German intensive care units[J]. Intensive Care Med, 2004, 30(6):1089-1096.
DOI
URL
|
[3] |
Intensive Care Antimicrobial Resistance Epidemiology (ICARE). Surveillance Report,data summary from January 1996 through December 1997:a report from the National Nosocomial Infections Surveillance(NNIS) System[J]. Am J Infect Control, 1999, 27(3):279-284.
DOI
URL
|
[4] |
FELMINGHAM D, WHITE A R, JACOBS M R, et al. The Alexander Project:the benefits from a decade of surveillance[J]. J Antimicrob Chemother, 2005, 56(Suppl 2):ii3-ii21.
|
[5] |
TURNER P J. Meropenem activity against European isolates:report on the MYSTIC(Meropenem Yearly Susceptibility Test Information Collection) 2006 results[J]. Diagn Microbiol Infect Dis, 2008, 60(2):185-192.
DOI
URL
|
[6] |
李婷婷, 韩冠英. 某院铜绿假单胞菌耐药性与抗菌药物使用量的相关性分析[J]. 中国医院药学杂志, 2016, 36(19):1689-1693.
|
[7] |
王晓坤, 黄新刚, 丁菊英. 病原菌耐药性与抗菌药物使用量的相关性分析[J]. 中华医院感染学杂志, 2017, 27(20):4576-4580.
|
[8] |
全国细菌耐药监测网. 2019年全国细菌耐药监测报告(简要版)[EB/OL]. (2020-11-19)[2020-12-01]. http://www.carss.cn/Report/Details?aId=770.
|
[9] |
胡付品, 郭燕, 朱德妹, 等. 2020年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2021, 21(4):377-387.
|
[10] |
CERCEO E, DEITELZWEIG S B, SHERMAN B M, et al. Multidrug-resistant gram-negative bacterial infections in the hospital setting:overview,implications for clinical practice,and emerging treatment options[J]. Microb Drug Resist, 2016, 22(5):412-431.
DOI
URL
|
[11] |
FU Q, ZONG Z. Interpretation of guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae,Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities[J]. West China Medical Journal, 2018.
|
[12] |
European Centre for Disease Prevention and Control(ECDC). Antimicrobial resistance surveillance in Europe 2015[EB/OL]. (2017-01-30)[2020-01-01]. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antimicrobial-resistance-europe-2015.pdf.
|
[13] |
VAN LOON K, VOOR IN'T HOLT A F, VOS M C. A systematic review and meta-analyses of the clinical epidemiology of carbapenem-resistant Enterobacteriaceae[J]. Antimicrobial Agents and Chemotherapy, 2018, 62(1):e01730-17.
|
[14] |
TORRES-GONZALEZ P, CERVERA-HERNANDEZ M E, NIEMBRO-ORTEGA M D, et al. Factors associated to prevalence and incidence of carbapenem-resistant Enterobacteriaceae fecal carriage:a cohort study in a Mexican Tertiary Care Hospital[J]. PLoS One, 2015, 10(10):e0139883.
DOI
URL
|
[15] |
LIPSITCH M, SAMORE M H. Antimicrobial use and antimicrobial resistance:a population perspective[J]. Emerg Infect Dis, 2002, 8(4):347-354.
DOI
URL
|
[16] |
MANIKAL V M, LANDMAN D, SAURINA G, et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn,New York:citywide prevalence,interinstitutional spread,and relation to antibiotic usage[J]. Clin Infect Dis, 2000, 31(1):101-106.
DOI
URL
|
[17] |
WILLIAMS V R, CALLERY S, VEARNCOMBE M, et al. The role of colonization pressure in nosocomial transmission of methicillin-resistant Staphylococcus aureus[J]. Am J Infect Control, 2009, 37(2):106-110.
DOI
URL
|